Edition:
India

Albireo Provides Mid-Year Clinical Development Update


Wednesday, 10 Jul 2019 

July 9 (Reuters) - Albireo Pharma Inc ::ALBIREO PROVIDES MID-YEAR CLINICAL DEVELOPMENT UPDATE.ALBIREO PHARMA INC - EXPECTS ODEVIXIBAT PEDFIC 1 PHASE 3 TOPLINE DATA MID-2020 -.ALBIREO PHARMA INC - SITE ACTIVATED FOR ODEVIXIBAT PEDFIC 2 EXPANDED OPEN-LABEL COHORT.ALBIREO PHARMA INC - ODEVIXIBAT BILIARY ATRESIA PIVOTAL TRIAL EXPECTED TO BEGIN IN 2020.ALBIREO PHARMA INC - MOVES INTO NASH WITH INITIATION OF ELOBIXIBAT PHASE 2 TRIAL.ALBIREO PHARMA INC - ENCOURAGED WITH RECRUITING EFFORTS BY PARTICIPATING SITES IN OUR PHASE 3 TRIAL FOR ODEVIXIBAT IN PFIC. 

Company Quote

20.81
 --
6 Dec 2019